SA55 broadly neutralizes SARS-CoV-2 and robustly prevents viral escape by JN.1 sublineages
SA55, a monoclonal antibody, strongly neutralizes SARS-CoV-2, including JN.1 subvariants.
New protocol from Japan enables high-affinity monoclonal antibody production from single B cells in 6 days.
Cost-effective and works across antibody types, including for SARS-CoV-2 spike protein.
Next generation medicines in fight against Covid:
Focusing specifically on the receptor-binding domain (RBD) rather than the entire SARS-CoV-2 spike protein provides enhanced, long-lasting protection against viral mutations